0001144204-15-007606.txt : 20150211 0001144204-15-007606.hdr.sgml : 20150211 20150210195240 ACCESSION NUMBER: 0001144204-15-007606 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150211 DATE AS OF CHANGE: 20150210 GROUP MEMBERS: ANDREW CADER SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDGENICS, INC. CENTRAL INDEX KEY: 0001138776 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980217544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-86182 FILM NUMBER: 15595750 BUSINESS ADDRESS: STREET 1: C/O MEDGENICS, INC. STREET 2: 435 DEVON PARK DRIVE, BLDG 700 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 1-646-239-1690 MAIL ADDRESS: STREET 1: C/O MEDGENICS, INC. STREET 2: 435 DEVON PARK DRIVE, BLDG 700 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MEDGENICS INC DATE OF NAME CHANGE: 20010419 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ACNYC LLC CENTRAL INDEX KEY: 0001519691 IRS NUMBER: 371457452 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 70 MEETING HOUSE ROAD CITY: MOUNT KISCO STATE: NY ZIP: 10549 BUSINESS PHONE: (914) 244-8763 MAIL ADDRESS: STREET 1: 70 MEETING HOUSE ROAD CITY: MOUNT KISCO STATE: NY ZIP: 10549 SC 13G/A 1 v401021_sc13ga.htm SCHEDULE 13G/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

 

 

 

Medgenics, Inc.

(Name of Issuer)

 

 

 

Common Stock, $.0001 Par Value Per Share

(Title of Class of Securities)

 

 

 

Common Stock: 58436Q203

(CUSIP Number)

 

 

 

December 31, 2014

(Date of Event Which Requires Filing of this Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨  Rule 13d-1(b)
x  Rule 13d-1(c)
¨  Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Persons who respond to the collection of information contained in this form are not

required to respond unless the form displays a currently valid OMB control number.

 

 
 
CUSIP NO.58436Q203  Schedule 13G Page 2 of 7

 

1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Andrew Cader

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

 

(a) ¨

(b) ¨

 

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

 

 

 

NUMBER OF SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

 

 

5

SOLE VOTING POWER

 

0 (1)

 

6

SHARED VOTING POWER

 

1,751,857.07 (1) (2)

 

7

SOLE DISPOSITIVE POWER

 

0 (1)

 

8

SHARED DISPOSITIVE POWER

 

1,751,857.07 (1) (2)

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,751,857.07 (1) (2)

 

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)                                              ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.91% (1) (2) (3)

 

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN

 

         

 

 

(1)Subject to the responses contained in Item 4 herein.
(2)Includes 1,197,722 shares of common stock par value $.0001 per share (“Common Stock”), of Medgenics, Inc. (the “Company”), plus warrants of the Company (“Warrants”) to purchase an additional 554,135.07 shares of Common Stock.
(3)See Item 4(b).

 

 

 

 
 

  

CUSIP NO.    58436Q203  Schedule 13G Page 3 of 7

 

1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

ACNYC LLC (Federal EIN # 37-1457452)

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

 

(a) ¨

(b) ¨

 

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

New York

 

 

 

NUMBER OF SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

 

 

5

SOLE VOTING POWER

 

0 (1)

 

6

SHARED VOTING POWER

 

1,751,857.07 (1) (2)

 

7

SOLE DISPOSITIVE POWER

 

0 (1)

 

8

SHARED DISPOSITIVE POWER

 

1,751,857.07 (1) (2)

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,751,857.07(1) (2)

 

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.91% (1) (2) (3)

 

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

 

         

 

(1)Subject to the responses contained in Item 4 herein.
(2)Includes 1,197,722 shares of Common Stock of the Company, plus Warrants to purchase an additional 554,135.07 shares of Common Stock.
(3)See Item 4(b).

 

 
 

 

Item 1(a).   Name of Issuer:
     
    Medgenics, Inc. (the “Company”)
     
Item 1(b).   Address of Issuer’s Principal Executive Offices:
     
    435 Devon Park Drive, Building 700
    Wayne, Pennsylvania 19087
     
Item 2(a).   Name of Person Filing:
     
    Andrew Cader
    ACNYC LLC
     
    (each, a “Reporting Person”, and collectively, the “Reporting Persons”)
     
Item 2(b).   Address of Principal Business Office or, if None, Residence:
     
    300 Beach Drive NE, Unit 2401  
    St. Petersburg, FL 33701
     
Item 2(c).   Citizenship:
     
  The responses provided in Row 4 on the cover page with respect to each Reporting Person are incorporated by reference herein in response to this Item 2(c).
     
Item 2(d).   Title of Class of Securities:
     
    Common Stock, par value $0.0001 per share
     
Item 2(e).   CUSIP Number:
     
    Common Stock:  58436Q203
     
Item 3.   If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    Not applicable.
     
Item 4.   Ownership.
     
    (a) Amount beneficially owned:  As of December 31, 2014, and subject to the information included in this Item 4, Mr. Cader beneficially owned 1,751,857.07 shares of Common Stock, all of which were owned by ACNYC LLC.  As required under regulations of the SEC, the number of shares beneficially owned includes 554,135.07 shares of Common Stock underlying Warrants held by ACNYC LLC.  
    The filing of this Schedule 13G shall not be construed as an admission that (a) either of the Reporting Persons are, for purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Schedule 13G or (b) that this Schedule 13G is legally required to be filed by each of the Reporting Persons.

 

Page 4 of 7
 

 

 

 

    (b) Percent of class:
     
    The responses provided in Row 11 on the cover page with respect to each Reporting Person are incorporated by reference herein in response to this Item 4(b).
     
    The percentage of the class of securities outstanding was based on a denominator of 25,356,788.07 shares of Common Stock outstanding, which number is calculated by adding (1) 24,802,653 shares of Common Stock outstanding as of December 1, 2014, based on information reported in the Company’s Prospectus Supplement on Form 424B5 filed with SEC on November 25, 2014 and the Company’s press release dated December 1, 2014 and (2) 554,135.07 shares of Common Stock underlying the Warrants held by the Reporting Persons.
     
    (c) Number of shares of Common Stock and Warrants as to which Mr. Cader and ACNYC LLC each have:

 

  (i) sole power to vote or to direct the vote:  0 shares of Common Stock.
     
  (ii) shared power to vote or to direct the vote:  1,751,857.07 shares of Common Stock (including 554,135.07 shares underlying the Warrants), all of which are owned of record by ACNYC LLC.
     
  (iii) sole power to dispose or to direct the disposition of:  0 shares of Common Stock.
     
  (iv) shared power to dispose or to direct the disposition of:  1,751,857.07 shares of Common Stock (including 554,135.07 shares underlying the Warrants), all of which are owned of record by ACNYC LLC.

  

     
Item 5.   Ownership of Five Percent or Less of a Class:
     
    Not applicable.
     
Item 6.   Ownership of More Than Five Percent on Behalf of Another Person:
     
    ACNYC LLC is the record and beneficial owner of 1,751,857.07 shares of Common Stock (including 554,135.07 shares of Common Stock underlying the Warrants) all of which are also beneficially owned by Mr. Cader, as the sole member of ACNYC LLC.  Thus, each of the Reporting Persons may have the right to receive or the power to direct the receipt of dividends from such shares of Common Stock and the proceeds from the sale of such shares of Common Stock and Warrants.
     
Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
     
    Not applicable.

 

Item 8.   Identification and Classification of Members of the Group:
     
    Not applicable.
     
Item 9.   Notice of Dissolution of Group:
     
    Not applicable.
     
Item 10.   Certifications
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.

 

 

Page 5 of 7
 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 

 

Date: February 9, 2015 /s/   Andrew Cader
  Andrew Cader
     

 

 

Date: February 9, 2015 ACNYC LLC
   
  By:  /s/   Andrew Cader
    Andrew Cader

 

 

Page 6 of 7
 

AGREEMENT

 

Pursuant to Securities Exchange Act

Rule 13d-1(k)(1)(iii)

 

The undersigned hereby agree that the Schedule 13G to which this Agreement relates, filed pursuant to the Securities Exchange Act of 1934 and executed by each of the undersigned of even date herewith, is filed on behalf of each of the undersigned.

 

DULY EXECUTED this 9th day of February, 2015. 

 

/s/   Andrew Cader
  Andrew Cader
     

 

 

ACNYC LLC
   
  By:  /s/   Andrew Cader
    Andrew Cader

 

 

Page 7 of 7